Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aspirin IV - Hyloris Pharmaceuticals

Next Previous
X
Search
Drug Profile

Aspirin IV - Hyloris Pharmaceuticals

Alternative Names: HY-073; HY-CVS-073; intravenous acetylsalicylic acid; intravenous aspirin; Rho-11

Latest Information Update: 20 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hyloris Pharmaceuticals
  • Developer Hyloris Pharmaceuticals; Rhoshan Pharmaceuticals
  • Class Analgesics; Antineoplastics; Antiplatelets; Antipyretics; Antirheumatics; Heart failure therapies; Nonsteroidal anti-inflammatories; Salicylic acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Coronary disorders

Highest Development Phases

  • Phase I Coronary disorders

Most Recent Events

  • 14 Mar 2024 Hyloris Pharmaceuticals plans to submit NDA for Coronary disorders in USA (IV)
  • 11 May 2022 Rhoshan Pharmaceuticals completes a phase I trial in Coronary disorders (In volunteers) in USA (IV)(NCT05166096)
  • 29 Dec 2021 Phase-I clinical trials in Coronary disorders (In volunteers) in USA (IV) (NCT05166096)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top